![Street Calls of the Week](https://i-invdn-com.investing.com/news/moved_small-LYNXNPEK330AM_L.jpg)
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1051 | 1037 | 1108 | 1140 | 1475 | 1927 |
Fund Return | 5.09% | 3.69% | 10.78% | 4.47% | 8.09% | 6.78% |
Place in category | - | - | - | - | - | - |
% in Category | - | - | - | - | - | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
LU0434928536 | 5.57B | 4.89 | 9.84 | 9.70 | ||
R BP US Premium Equities F | 5.57B | 4.95 | 10.66 | 10.53 | ||
R BP US Premium Equities I | 5.57B | 4.96 | 10.81 | 10.67 | ||
LU1549401203 | 5.15B | 4.65 | 8.00 | - | ||
R BP Global Premium Equities B | 5.15B | 4.43 | 9.96 | 8.37 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Invesco JapEqAdvantage A EUR H AccE | 67.44B | 2.19 | 12.49 | 8.04 | ||
Invesco JapEqAdvantage C EUR H AccE | 67.44B | 2.26 | 13.46 | 8.89 | ||
LU1482751903 | 472.65M | 19.62 | 9.30 | - | ||
LU1841614867 | 284.41M | 3.54 | 11.65 | - | ||
Morgan Stanley Global Brands AH | 20.93B | 4.88 | 2.24 | 7.42 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
JPMorgan | US46625H1005 | 2.54 | 276.59 | +0.10% | |
Oracle | US68389X1054 | 2.45 | 174.16 | +0.17% | |
Corpay | US2199481068 | 2.21 | 377.31 | +2.42% | |
Bristol-Myers Squibb | US1101221083 | 2.13 | 53.90 | -3.70% | |
CRH | IE0001827041 | 2.04 | 8,520.0 | +1.28% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Strong Buy | Buy |
Technical Indicators | Strong Sell | Strong Buy | Strong Buy |
Summary | Neutral | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review